A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.

NPJ Breast Cancer · 2022 · PMC8938486 · PMID 35314692

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

at the limit of significanceno p-value reported

The Cox proportional hazards model, including the same significant parameters described in Table 8 , revealed an adjusted hazard ratio for the OS of the favorable genetic profile of 0.71 (95% CI, 0.5–1.01; p = 0.058), at the limit of significance.

also in 326 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.